GoAI
Get started
GeneDx Holdings Corp. logo

GeneDx Holdings Corp.

WGS

NASDAQHealthcareMedical - Diagnostics & Research

Open in GoAI

Previous close

$87.065

+$4.515 · +5.47%

Aug 21, 4:00 PM ET

Pre-market

$87.00

−$0.065 · -0.07%

Aug 24, 6:29 AM ET

WGS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

76

Undervalued

Momentum

38

Weakening

Sentiment

43

Mixed

Risk resilience

29

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

GeneDx Holdings Corp. functions as a health intelligence firm singularly focused on the individual patient. It aims to revolutionize healthcare delivery by deploying advanced artificial intelligence and machine learning capabilities. These sophisticated algorithms are applied to vast, longitudinal clinical and genomic datasets to construct comprehensive, dynamic models of human health, ultimately defining personalized, optimal pathways for each person's well-being. Through its exclusive Centrellis health intelligence platform, the company gains profound insights into both disease states and overall wellness, enabling it to furnish evidence-based solutions for the most critical medical challenges. Eric Schadt established the corporation in October 2015, and its principal offices are located in Stamford, Connecticut.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
US
CEO
Katherine A. Stueland
Listed since
Nov 4, 2020
Employees
1,300

Market position

Day range

Current $87.065

52-week range

Current $87.065

Open
$82.90
Previous close
$82.55
Volume
555.28K
0.48× average
Average volume
1.15M
Average daily volume
Market cap
2.6B USD
Beta
1.98
Market reference 1
50-day average
$67.7692
+28.47% above average
200-day average
$87.2819
-0.25% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
3.54B USD
P/E (TTM)
-23.92×
P/B (TTM)
10.59×
P/S (TTM)
5.71×
EV / EBITDA
534.93×
Earnings yield
-0.60%
Free cash flow yield
0.41%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
68.20%
Operating margin
-13.34%
Net margin
-23.40%
Return on equity
-6.82%
Return on assets
-3.69%
Return on invested capital
-2.50%

Financial health

Debt / equity
0.69×
Current ratio
2.46×
Altman Z-score
3
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends105%-37%-178%-320%Gross margin, FY2021: -7.82%Gross margin, FY2022: -11.40%Gross margin, FY2023: 44.43%Gross margin, FY2024: 63.64%Gross margin, FY2025: 69.74%Operating margin, FY2021: -210.25%Operating margin, FY2022: -284.48%Operating margin, FY2023: -89.15%Operating margin, FY2024: -7.60%Operating margin, FY2025: -2.76%Net margin, FY2021: -115.64%Net margin, FY2022: -233.91%Net margin, FY2023: -86.77%Net margin, FY2024: -17.12%Net margin, FY2025: -4.92%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -7.82%. Gross margin FY2022 -11.40%. Gross margin FY2023 44.43%. Gross margin FY2024 63.64%. Gross margin FY2025 69.74%. Operating margin FY2021 -210.25%. Operating margin FY2022 -284.48%. Operating margin FY2023 -89.15%. Operating margin FY2024 -7.60%. Operating margin FY2025 -2.76%. Net margin FY2021 -115.64%. Net margin FY2022 -233.91%. Net margin FY2023 -86.77%. Net margin FY2024 -17.12%. Net margin FY2025 -4.92%.

Income trends

Revenue

427.54M USD+39.97%

Operating income

−11.8M USD+49.16%

Net income

−21.02M USD+59.80%
Income trends across reported periods537.06M USD98.98M USD−339.09M USD−777.17M USDRevenue, FY2021: 212.2M USDRevenue, FY2022: 234.69M USDRevenue, FY2023: 202.57M USDRevenue, FY2024: 305.45M USDRevenue, FY2025: 427.54M USDOperating income, FY2021: −446.15M USDOperating income, FY2022: −667.65M USDOperating income, FY2023: −180.6M USDOperating income, FY2024: −23.21M USDOperating income, FY2025: −11.8M USDNet income, FY2021: −245.39M USDNet income, FY2022: −548.98M USDNet income, FY2023: −175.77M USDNet income, FY2024: −52.29M USDNet income, FY2025: −21.02M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 212.2M USD. Revenue FY2022 234.69M USD. Revenue FY2023 202.57M USD. Revenue FY2024 305.45M USD. Revenue FY2025 427.54M USD. Operating income FY2021 −446.15M USD. Operating income FY2022 −667.65M USD. Operating income FY2023 −180.6M USD. Operating income FY2024 −23.21M USD. Operating income FY2025 −11.8M USD. Net income FY2021 −245.39M USD. Net income FY2022 −548.98M USD. Net income FY2023 −175.77M USD. Net income FY2024 −52.29M USD. Net income FY2025 −21.02M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue427.54M USD305.45M USD202.57M USD234.69M USD212.2M USD
Cost of goods sold129.37M USD111.05M USD112.56M USD261.44M USD228.8M USD
Gross profit298.17M USD194.4M USD90.01M USD−26.75M USD−16.6M USD
Research and development72.03M USD45.72M USD58.27M USD86.2M USD105.16M USD
Selling, general, and administrative239.22M USD168.48M USD194.71M USD338.24M USD318.73M USD
Operating expenses311.25M USD217.61M USD270.6M USD640.9M USD429.55M USD
Interest income——1.11M USD2.54M USD79K USD
Interest expense2.54M USD3.03M USD—3.21M USD2.84M USD
Depreciation and amortization25.22M USD21.95M USD33.73M USD59.31M USD21.81M USD
Operating income−11.8M USD−23.21M USD−180.6M USD−667.65M USD−446.15M USD
Net income−21.02M USD−52.29M USD−175.77M USD−548.98M USD−245.39M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

11 ratings
Strong buy00%
Buy1091%
Hold19%
Sell00%
Strong sell00%

WGS news

zacks.com

Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?

GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Read source
seekingalpha.com

GeneDx: Why I Think The Worst Is Behind The Business

GeneDx shows early signs of operational recovery, with Q2 revenue and margins exceeding expectations and testing volumes up 32%. Reimbursement rates have stabilized, and management expects meaningful improvements in Q4…

Read source
gurufocus.com

Is GeneDx Holdings Corp (WGS) Overvalued After 5.1% Rally? GF Value Says Overvalued

On August 11, 2026, GeneDx Holdings Corp (WGS) shares rose 5.1% to $81.83, bouncing back in a volatile market. Over the past 52 weeks, the stock has traded betw

Read source
businesswire.com

GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx launches a new online offering to expand access to exome testing and help more children and families get answers sooner.

Read source
defenseworld.net

GeneDx Holdings Corp. $WGS Shares Acquired by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its position in GeneDx Holdings Corp. (NASDAQ: WGS) by 143.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The…

Read source
businesswire.com

GeneDx to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced that company management will participate in the Canaccord Genuity and Wells Fargo investor conferences.

Read source

Corporate actions

Corporate action history

Stock split

Effective May 4, 2023

1:33

WGS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding WGS

Funds reporting this stock among their holdings, ordered by reported position size.

ARK Innovation ETF logoARK Innovation ETFARKK
Market value
84.35M
Weight
1.27%
AUM
5.56B USD
Expense ratio
0.75%
Price / 1D
$86.21+3.53%
ARK Genomic Revolution ETF logoARK Genomic Revolution ETFARKG
Market value
45.41M
Weight
2.19%
AUM
1.56B USD
Expense ratio
0.75%
Price / 1D
$49.45+3.80%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
42.53M
Weight
0.05%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
39.57M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Thrivent Small-Mid Cap Equity ETF logoThrivent Small-Mid Cap Equity ETFTSME
Market value
17.92M
Weight
1.84%
AUM
968.94M USD
Expense ratio
0.65%
Price / 1D
$48.61+0.81%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
16.43M
Weight
0.02%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
15.24M
Weight
0.10%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
9.06M
Weight
0.04%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%

Continue in GoAI

Research WGS

research.disclaimer